Prevention of tuberculosis in patients treated with tumour necrosis factor antagonists;Zapobieganie gruźlicy u chorych leczonych antagonistami czynnika martwicy nowotworów

Reumatologia

Volumn 48, Issue 1, 2010, Pages 4-13

  Korzeniewska Koseła, Maria ^a  

^a Kierownik Zakładu ^*  (Poland)

Author keywords

Chemoprophylaxis; Latent tuberculosis infection; TNF antagonists; Tuberculosis

Indexed keywords

EID: 77952157918     PISSN: 00346233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Kucharz FJ, Korzeniewska-Koseta M, Kotulska A Zalecenia postçpowania w zapobieganiu i leczeniu gruźlicy u chorych leczonych antagonistami TNF-α. Reumatologia 2008; 46: 51-54.
2. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
3. Gordon S, Mwandumba H. Respiratory tuberculosis. In: Clinical tuberculosis. Davies PDO, Barnes PF, Gordon SB (ed.). Fourth edition. Hodder Arnold, London 2008; 145-162.
4. Jasmer RM, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United states and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004; 170: 1360-1366.
5. Gruźlica i choroby układu oddechowego w Polsce w 2008 r. Korzeniewska-Koseta M (red.). Instytut Gruźlicy i Chorób Płuc, Warszawa 2009.
6. Lewandowska K. Czȩstošč wystȩpowania utajonego zakażenia Mycobacterium tuberculosis okrešlana przy pomocy odczynu tuberkulinowego i testu wydzielania interferonu-gamma w próbie populacji ogólnej i osadzonych w zakładach karnych województwa mazowieckiego. 2009. Praca doktorska (przygotowana do obrony).
7. Goła̧b J, Jakóbisiak M. Cytokiny. W: Immunologia Goła̧b J, Jakóbisiak M, Lasek W, Stokłosa T. (red.). Wydawnictwo Naukowe PWN, Warszawa 2008; 108-152.
8. Wallis RS. Tumor necrosis factor antagonists: structure, function and tuberculosis risks. Lancet Infect Dis 2008; 8: 601-611.
9. Lin J, Ziring D, Desai S. TNF-α blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008; 126: 13-30. (Pubitemid 350266448)
10. Furst DE The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2008, Dec 29 (Epub ahead of print).
11. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59: 209-217.
12. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
13. Skvara H, Duschek N, Karlhofer F. de novo tuberculosis during infliximab therapy in a patent with Behcet disease. J Dtsch Dermatol Ges 2009; 7: 616-619.
14. Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009; 22: 403-409.
15. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-379. (Pubitemid 38198820)
16. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-1265. (Pubitemid 38608568)
17. Gómez-Reino JJ, Carmona L, Descalzo MÁ, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761. (Pubitemid 46932080)
18. Screening for tuberculosis before TNF-α antagonist initiation: Are current methods good enough? Joint Bone Spine 2008; 75: 112-115.
19. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune response to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973.
20. Villiger PM, Zellweger JP, Möller B. Novel screening tools for latent tuberculosis: time to leave an old friend? Curr Opin Rheumatol 2009; 21: 238-243.
21. Berkel GM, Cobelens FG, de Vries G, et al. Tuberculin skin test: estimation of positive and negative predictive values from routine data lnt J Tuberc Lung Dis 2005; 9: 310-316.
22. Mutlu GM, Mutlu EA, Bellmeyer A, Rubinstein I. Pulmonary adverse events of anti-tumor necrosis factor-α antibody therapy. Am J Med 2006; 119: 639-646. (Pubitemid 44128443)
23. Greenberg JD, Reddy SM, Schloss SG, et al. Comparison of an in vitro tuberculosis interferon-gamma assay with delayedtype hypersensitivity testing for detection of latent Mycobacterium tuberculosis: A pilot study in rheumatoid arthritis. J Rheumatol 2008; 35: 770-775.
24. Zabana Y, Domenech E, San Roman AL, et al. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis 2008; 14: 1387-1391.
25. Tissot F, Zanetti G, Francioli P, et al. Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005; 40: 211-217.
26. Aydin M, Cagatay T, Sunmez S, et al. Follow up results of patients receiving anti tumor necrosis factor antagonists and evaluation of risk of tuberculosis. Eur Respir J 2009; (Suppl. 53) 34: 455.
27. Symmons DR Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Clin Rheumatol 2002; 16: 707-722.
28. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 2: 309-313.
29. Pai M. Guidelines on IGRAs: concordant or discordant. 2nd Global Symposium on IGRAs. May 30-June 1, 2009, Dubrovnik, Croatia. Wykład dostȩpny na stronie internetowej http://www.igrasymposium.com/index.html
30. Pai M, O'Brien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects. Sem Respir Crit Care Med 2008; 29: 560-568.
31. Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell- based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006; 28: 31-34. (Pubitemid 44914257)
32. Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and TST are both useful for latent TB screening in autoimmune diseases. Eur Respir J 2009; 33: 586-593.
33. Lalvani A, Thillai M. Diagnosis of tuberculosis: principles and practice of using interferon-gamma release assays (IGRAs). Breathe 2009; 5: 303-309.
34. Diel R, Hauer B, Loddenkemper R, et al. Empfelungen für das Tuberkulosescreening vor Gabe von TNF-alpha-inhibitoren bei rheumatischen Erkrankungen. Pneumonologie 2009; 63: 329-334.
35. Beglinger Ch, Dudler J, Mottet Ch, et al. Screening for tuberculosis infection before initiation of anti-TNF-alpha therapy. Swiss Med Wkly 2007; 137: 621-622. (Pubitemid 350114753)
36. Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antygen-specific interferon-gamma assay. Ann Rheum Dis 2008; 67: 84-90.
37. Martin J, Walsh C, Gibbs A, et al. Comparison of interferon-gamma-release assays and conventional screening tests before tumor necrosis factor-alpha blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010; 69: 181-185.
38. Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008; 27: 907-913.
39. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunosorbent assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008; 35: 1271-1276. (Pubitemid 352000770)
40. Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009; 161: 797-800.
41. Efthimiou P, Sood S. Quantiferon TB gold test: The new standard for screening of latent tuberculosis in patients with rheumatoid arthritis? Ann Rheum Dis 2007; 66: 276.
42. Raval A, Akhavan-Toyserkani G, Brinker A, et al. Characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007; 147: 699-702. (Pubitemid 351664465)
43. Chen DY, Shen GH, Hsieh TY, et al. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008; 59: 800-806.
44. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al. Attenuated response to purified protein derivate in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360-1361. (Pubitemid 41206259)
45. Sellam J, Hamdi H, Roy C, et al. Comparison of in vitro- specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007; 66: 1610-1615. (Pubitemid 350205449)
46. Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 2799-2806.
47. Sichletidis L, Settas L, Spyratos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10: 1127-1132. (Pubitemid 44519351)
48. Theis VS, Rhodes JM. Minimizing tuberculosis during antitumor necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27: 19-30. (Pubitemid 350212629)
49. Carmona L, Gömez-Reino JJ, Rodriguez-Valverde V, et al. BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772.
50. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60: 800-805. (Pubitemid 41475202)
51. Sterling TR. New approaches to the treatment of latent tuberculosis. Sem Respir Crit Care Med 2008; 29: 532-541.
52. Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lun Dis 2008; 12: 1352-1364.
53. Den Breeder AA, Vonkeman H, Creemers MCW, et al. Characteristics of tuberculosis during anti-TNF treatment in RA patients in the Netherlands and influence of pre-treatment screening and treatment. Ann Rheum Dis 2005; 64 (Suppl III): 82.
54. Escalante P. In the clinic. Tuberculosis. Ann Intern Med 2009; 150, ITC 6.1- 6.14.
55. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the BSR Biologics Register (BSRBR). EULAR 2008 (THU0134). Ann Rheum Dis 2008; 67 (Suppl II): 178.